Special items: Ovarian Cancer and Us blog best viewed in Firefox

Thursday, January 19, 2012

Myriad Genetics Gets (Worldwide) Rights To RAD51C Gene

"...Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.